Clinical Trial Search

Primary: Number of Pelvic-ureter-units (PUUs) Detected With Vesicoureteral Reflux by Contrast Enhanced Voiding Urosonography (ceVUS) and by Voiding Cystourethrography (VCUG)…

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/California/7/2009 Strain of Influenza Disease — 780.2; 533.6 Titers

Primary: Number of Participants With a Treatment Response — 38; 17 Participants

Primary: Percentage of Subjects With Seropositivity Rates for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity) — 16.7; 83.3; 16.7; 66.7 % of subjects

Primary: Time to Treatment Failure — 4.5; 6.9 Months

Primary: Safety - Most Frequently Reported Adverse Events and Grade — 5; 9; 0; 4 adverse events

Primary: Safety - Most Frequently Reported Adverse Events and Grade — 3; 10; 0; 2 Number of adverse events

Primary: Emotion Recognition Questionnaire — 18.67; 17.00; 17.00; 16.40 score on a scale

Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants

Primary: Mean Change From Baseline in the Number of Migraine Headache Days in the Last 28-Day Period of the 12-Week Treatment Phase — -3.66; -4.23; -3.92; -4.80 Days

Primary: Response Rate: Number of Participants With Objective Tumor Response — 12; 14; 20 Participants

Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 4 — 0.065; 0.017 Liters — p=0.282

Primary: Change in Verbal Fluency FAS (F, A or S Words) Total Score — 38.8; 41.0; 32.8; 30.8 Words

Primary: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Clinical Remission at Week 12 — 15.4; 19.5; 36.6; 28.0 percentage of participants — p=0.0955

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug Discontinuation — 1; 3; 2; 7 Participants